Blockchain Registration Transaction Record

Tonix Data Reveals Opioid Overuse in Fibromyalgia Despite Guidelines

Tonix Pharmaceuticals reveals opioid use remains common in fibromyalgia patients despite guidelines. New data highlights need for non-opioid treatments like TONMYA.

This news matters because it exposes a dangerous disconnect between medical guidelines and real-world practice: opioids continue to be overprescribed for fibromyalgia, contributing to the opioid crisis. Tonix's data underscores the importance of adopting newer, non-opioid therapies like TONMYA, which could reduce addiction risks and improve patient outcomes. For the millions living with fibromyalgia, this highlights the need for both patients and doctors to question opioid prescriptions and explore safer, FDA-approved alternatives.